BioSpace News Archive

Neovasc Inc . (“Neovasc” or the “Company”) ( Nasdaq , TSX : NVCN) announced today that it has received a “not-approvable” letter from U.S. Food & Drug Administration (FDA) regarding its PMA submission for the Neovasc Reducer™ (Reducer). Fred Colen, Neovasc CEO, said, “While we are disappointed in FDA’s decision, the letter was not unexpected, given the outcome of the Panel meeting.” He continued, “Milli

Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter and full-year 2020 financial results on Friday, January 29, 2021 . Lilly will also conduct a conference call on that day with the investment community and media to further detail the company’s financial performance. The conference call will begin at 9 a.m. Easter

Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and gaseous NO (gNO) for the treatment of solid tumors, today announced that it will report financial results for its third fiscal quarter ended December 31, 2020 on Tuesday, Februa

Cipher Pharmaceuticals Inc. (TSX: CPH) (“Cipher” or “the Company”) today announced it has received an arbitration award in the previously announced dispute between the Company and Bausch Health Ireland (“Bausch Health”) relating to the License, Development and Commercialization Agreement (the “Agreement”) of Trulance®

- DARZALEX FASPRO® Utilizing ENHANZE® Represents First and Only Approved Treatment for Patients with Newly Diagnosed AL Amyloidosis - - Accelerated Approval of DARZALEX FASPRO®-based Combination Regimen Supported by the PHASE 3 ANDROMEDA Study Demonstrating a Significantly Higher Hematologic Complete Response Rate in this Rare and Serious Blood Cell Disorder -